Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
High blood pressure is one of those silent health risks that often goes unnoticed until it causes serious harm. Besides diet, ...
Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.
aBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK Heart failure is a complex clinical syndrome ...
In a breakthrough for diagnostics, scientists have created an easy and effective test that identifies a heart failure biomarker in saliva, opening the door to more rapid and accessible life-saving ...
Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...
LBBB is linked to electrical abnormalities, causing inefficient heart pumping, dilation, and systolic dysfunction. The study found LBBB associated with increased heart failure risk, surpassing other ...
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Heart failure presents a critical health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback